| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Teknimed Inks Deal With Smith & Nephew
Posted on 05/16/2007 05:19:02 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel
Teknimed, a privately held French company that makes biomaterials for bone surgery, has signed a deal to allow Smith & Nephew (SNN) to market its FDA-approved bone cement. Smith & Nephew’s Orthopaedic Trauma & Clinical Therapies division will distribute, market and sell the product, called Spine Fix, in North America, Europe and Australia. Spine Fix is used to treat painful compression fractures in the spine. It is a ready-to-use, self-hardening bone cement that is injected into the vertebrae through a minimally invasive procedure known as a vertebroplasty or kyphoplasty. Procedures using Spine Fix, which are meant to reduce pain and improve mobility, can take less than one hour; pain relief can be felt as quickly as 25 minutes following the procedure.
Spine Fix has been approved in Europe since 2003. In 2006, it got the go ahead in the U.S., where Smith & Nephew plans to launch it officially in the third quarter of this year. The market for Spine Fix is substantial, with more than 700,000 spinal compression fractures occurring each year and more than 10 million people suffering from osteoporosis.
Source: Med Tech Sentinel
RELATED READING:
- BlueSky May Make $110 Million off Smith & Nephew Deal
_________________
Med Tech Sentinel
Teknimed, a privately held French company that makes biomaterials for bone surgery, has signed a deal to allow Smith & Nephew (SNN) to market its FDA-approved bone cement. Smith & Nephew’s Orthopaedic Trauma & Clinical Therapies division will distribute, market and sell the product, called Spine Fix, in North America, Europe and Australia. Spine Fix is used to treat painful compression fractures in the spine. It is a ready-to-use, self-hardening bone cement that is injected into the vertebrae through a minimally invasive procedure known as a vertebroplasty or kyphoplasty. Procedures using Spine Fix, which are meant to reduce pain and improve mobility, can take less than one hour; pain relief can be felt as quickly as 25 minutes following the procedure.Spine Fix has been approved in Europe since 2003. In 2006, it got the go ahead in the U.S., where Smith & Nephew plans to launch it officially in the third quarter of this year. The market for Spine Fix is substantial, with more than 700,000 spinal compression fractures occurring each year and more than 10 million people suffering from osteoporosis.
Source: Med Tech Sentinel
RELATED READING:
- BlueSky May Make $110 Million off Smith & Nephew Deal
_________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Tue Jul 15, 2008 08:25AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Mon Jul 14, 2008 02:18AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home